Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target

in Journal of Molecular Endocrinology
Authors:
Masaki ShiotaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Search for other papers by Masaki Shiota in
Current site
Google Scholar
PubMed
Close
,
Akira YokomizoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Search for other papers by Akira Yokomizo in
Current site
Google Scholar
PubMed
Close
, and
Seiji NaitoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Search for other papers by Seiji Naito in
Current site
Google Scholar
PubMed
Close
View More View Less

Free access

Few effective therapies exist for the treatment of castration-resistant prostate cancer (CRPC). Recent evidence suggests that CRPC may be caused by augmented androgen/androgen receptor (AR) signaling, generally involving AR overexpression. Aberrant androgen/AR signaling associated with AR overexpression also plays a key role in prostate carcinogenesis. Although AR overexpression could be attributed to gene amplification, only 10–20% of CRPCs exhibit AR gene amplification, and aberrant AR expression in the remaining instances of CRPC is thought to be attributed to transcriptional, translational, and post-translational mechanisms. Overexpression of AR at the protein level, as well as the mRNA level, has been found in CRPC, suggesting a key role for transcriptional regulation of AR expression. Since the analysis of the AR promoter region in the 1990s, several transcription factors have been reported to regulate AR transcription. In this review, we discuss the molecules involved in the control of AR gene expression, with emphasis on its transcriptional control by transcription factors in prostate cancer. We also consider the therapeutic potential of targeting AR expression.

Abstract

Few effective therapies exist for the treatment of castration-resistant prostate cancer (CRPC). Recent evidence suggests that CRPC may be caused by augmented androgen/androgen receptor (AR) signaling, generally involving AR overexpression. Aberrant androgen/AR signaling associated with AR overexpression also plays a key role in prostate carcinogenesis. Although AR overexpression could be attributed to gene amplification, only 10–20% of CRPCs exhibit AR gene amplification, and aberrant AR expression in the remaining instances of CRPC is thought to be attributed to transcriptional, translational, and post-translational mechanisms. Overexpression of AR at the protein level, as well as the mRNA level, has been found in CRPC, suggesting a key role for transcriptional regulation of AR expression. Since the analysis of the AR promoter region in the 1990s, several transcription factors have been reported to regulate AR transcription. In this review, we discuss the molecules involved in the control of AR gene expression, with emphasis on its transcriptional control by transcription factors in prostate cancer. We also consider the therapeutic potential of targeting AR expression.

Introduction

The androgen/androgen receptor (AR) signaling pathway is known to play a critical role in prostate tumorigenesis and prostate cancer (PCa) progression. Androgen-deprivation therapy (ADT) either reduces the production of androgens by surgical or medical castration, or interferes with the activity of the AR through the use of anti-androgens (Miyamoto et al. 2004). ADT is initially effective in about 90% of PCa cases, but these eventually circumvent ADT and emerge as castration-resistant PCa (CRPC; Roy-Burman et al. 2005). However, the androgen/AR signaling pathway remains a key determinant of cell proliferation in CRPC, despite low levels of available androgens following ADT (Litvinov et al. 2003). The reactivation of the androgen/AR signaling pathway in CRPC has been attributed to a number of mechanisms, including AR hypersensitivity, local intracrine production of androgens, promiscuous activation of the AR by adrenal androgens, non-androgenic steroids and even anti-androgens, and activation of the AR by growth factors and cytokines (Debes & Tindall 2004, Titus et al. 2005). These phenomena may result from abnormalities of the AR itself (AR mutation and overexpression) and/or its related molecules (AR cofactors). Furthermore, several kinds of AR splice variants displaying significant constitutive activity in the absence of ligand-binding have recently been reported by several laboratories (Dehm et al. 2008, Guo et al. 2009, Hu et al. 2009, Sun et al. 2010). Many studies have shown that progression to CRPC is associated with AR overexpression, and that AR inhibition represses tumor growth in PCa, even in CRPC (Gregory et al. 1998, Zegarra-Moro et al. 2002, Chen et al. 2004a,b, Scher & Sawyers 2005). Less than 10% of CRPC cases were found to possess somatic AR gene mutations (Taplin et al. 2003). In addition, the AR is upregulated in most CRPCs, of which only 10–20% exhibit amplification of the AR gene (Linja et al. 2001), indicating that increased AR expression in CRPC may result from factors other than gene amplification. The molecular mechanisms underpinning the aberrant AR expression have thus been intensively investigated as a potential source of novel therapeutic targets.

Although the expression of proteins, including AR protein, is regulated by various steps (transcription, translation, and post-translational control), the transcriptional step is generally thought to play a critical role in gene expression. In addition, AR overexpression has been detected at both the protein and mRNA levels in CRPC, suggesting that transcriptional regulation of the AR gene is at least one of the major causes of AR dysregulation. In this review, we therefore summarize the factors involved in AR expression, with an emphasis on transcriptional regulation by transcription factors in PCa (Table 1). Furthermore, we also discuss the therapeutic potential of targeting AR expression for the treatment of PCa and CRPC, by considering the agents involved in the regulation of AR expression (Table 2).

Table 1

Transcription factor-related factors regulating human androgen receptor (AR) expression in prostate cancer

FactorGene classificationGene functionCellsEffectDirect or indirectSupposed mechanismReferences
CREBTranscription factorInduction of genes in response to hormonal stimulation of the cAMP pathwayLNCaP+DirectBinding to CRE siteMizokami et al. (1994)
MycTranscription factorCell cycle progression, apoptosis, and cellular transformationVitro+DirectBinding to E-boxGrad et al. (1999)
MycTranscription factorCell cycle progression, apoptosis, and cellular transformationLNCaP+IndirectBinding to E-boxLee et al. (2009)
c-JunTranscription factorTransforming geneLNCaPDirectBinding to TRE sitePan et al. (2003)
c-JunTranscription factorTransforming geneLNCaPDirectBinding to TRE siteYuan et al. (2004)
Sp1Transcription factorConstitutive induction of genesVitro+DirectBinding to GC-boxFaber et al. (1993)
Sp1Transcription factorConstitutive induction of genesLNCaP+DirectBinding to GC-boxYuan et al. (2005)
p53Transcription factorCell cycle arrest, apoptosis, senescence, DNA repair, and metabolismLNCaPDirectBinding to p53-binding siteAlimirah et al. (2007)
Foxo3aTranscription factorTrigger for apoptosisLNCaP+DirectBinding to Foxo-response  elementYang et al. (2005)
LEF1Transcription factorHair cell differentiation, follicle morphogenesis, and cellular transformationLNCaP+DirectBinding to LEF/TCF-binding  siteYang et al. (2006)
LEF1Transcription factorHair cell differentiation, follicle morphogenesis, and cellular transformationLNCaP,  AI-LNCaP+DirectBinding to LEF/TCF-binding  siteLi et al. (2009)
Wnt-1CytokineOncogenesis and developmental processesLNCaP+IndirectActivation of β-cateninYang et al. (2006)
β-CateninSignal transductionCell growth and adhesionLNCaP+DirectActivation of LEF1 and  LEF1 complexYang et al. (2006)
PurαTranscription factorDNA replication and transcriptionLNCaP,  AI-LNCaPDirectBinding to suppressor element  (ARS) binding sitesWang et al. (2008)
NFκBTranscription factorCellular transformation and  inflammationLNCaP+DirectBinding to NFκB-binding siteZhang et al. (2009)
Twist1Transcription factorDifferentiation, epithelial– mesenchymal transitionLNCaP,  22Rv1,  CxR+DirectBinding to E-boxShiota et al. (2010)
E2F1Transcription factorCell cycle progressionLNCaPDirectBinding to E2F-binding siteDavis et al. (2006)
E2F1, E2F3Transcription factorCell cycle progressionLNCaP+DirectBinding to E2F-binding siteSharma et al. (2010)
Rb1Transcription cofactorCell cycle arrest and tumor  suppressorLNCaP, LAPC-4DirectInhibition of E2F1  transactivationSharma et al. (2010)
SREBP-1Transcription factorSterol biosynthesisLNCaP,  C4-2+DirectBinding to sterol regulatory elementHuang et al. (2010)
β2-MicroglobulinMembrane proteinEndocytosis of ironLNCaP,  C4-2+IndirectActivation of SREBP-1Huang et al. (2010)
Interleukin-8CytokineInflammationLNCaP,  22Rv1+IndirectActivation of NFκB and AP-1Seaton et al. (2008)
Endothelin-1HormoneVasoconstrictorLNCaP+IndirectActivation of MycLee et al. (2009)
HB-EGFGrowth factorMitogenic factor (ErbB1  agonist)LNCaPIndirectInhibition of AR transcriptionAdam et al. (2002)
Activin AGrowth factorTGF-β superfamilyLNCaP+IndirectActivation of SmadsKang et al. (2009)
Smad2, 3Signal transductionCell proliferation, apoptosis,  and differentiationLNCaP+DirectActivation of AR transcriptionKang et al. (2009)
Nemo-like kinase  (NLK)KinaseMAPK-like kinaseLNCaPIndirectInhibition of LEF1 and LEF1  complexEmami et al. (2009)
ErbB3-binding  protein 1 (EBP1)RNA-binding proteinGrowth regulation and differentiationLNCaPDirectInhibition of AR transactivationZhang et al. (2005)
Angiotensin II  type 1HormoneVasoconstrictorLNCaP+IndirectActivation of NFκB and  c-mycHoshino et al. (2010)
AT1RReceptorVasoconstrictorLNCaP+IndirectActivation of NFκB and  c-mycHoshino et al. (2010)

+/−, up/downregulation of androgen receptor.

Table 2

Agents involved in androgen receptor expression

Small moleculeMajor functionCellsEffectAction levelSupposed mechanismReferences
Natural compounds
 EGCGPolyphenolLNCaPTranscriptionInhibition of Sp1Ren et al. (2000)
 Theaflavin-3,3′-digallate (TF3)PolyphenolLNCaPPost-translationalInhibition of rat liver microsomal 5α-reductase activityLee et al. (2004)
 Penta-O-galloy-β-d-glucose (5GG)PolyphenolLNCaPPost-translationalInhibition of rat liver microsomal 5α-reductase activityLee et al. (2004)
 QuercetinPolyphenolLNCaPTranscriptionNAXing et al. (2001)
 QuercetinPolyphenolLNCaPTranscriptionActivation of c-JunYuan et al. (2004)
 ResverolPolyphenolLNCaPTranscriptionActivation of c-JunYuan et al. (2004)
 QuercetinPolyphenolLNCaPTranscriptionInhibition of Sp1Yuan et al. (2005)
 Genistein combined polysaccharide (GCP)PolyphenolLNCaPNon-transcriptionNATepper et al. (2007)
 Leteolin (3′,4′,5,7-tetrahydroxyflavone)PolyphenolLNCaPTranscriptionNAChiu & Lin (2008)
 Indole-3-carbinolCompound found in vegetablesLNCaPTranscriptionNAHsu et al. (2005)
 Phenethyl isothiocyanate (PEITC)Compound found in vegetablesLNCaPTranscriptionInhibition of Sp1Wang et al. (2006)
 d,l-sulforaphane (SFN)Compound found in vegetablesLNCaP, C4-2TranscriptionNASu-Hyeong & Shivendra (2009)
 BaicalinPolyphenol (component of PC-SPES)LNCaPNANAChen et al. (2001)
 BaicaleinPolyphenol (component of PC-SPES)LNCaPNANAChen et al. (2001)
 ThymoquinoneComponent of herbsLNCaP, C4-2NANAKaseb et al. (2007)
 Gum masticNatural resinLNCaPTranscriptionNAHe et al. (2006)
 Acetyl-11-keto-β-boswellic acid (AKBA)Natural resinLNCaPTranscriptionInhibition of Sp1Yuan et al. (2008)
Selenium
 Methylselenocysteine (MSC)Organic selenium-containing compoundsLNCaPNANALee et al. (2006)
 Methylseleninic acid (MSA)Organic selenium-containing compoundsLNCaPTranscriptionNAChun et al. (2006)
 1,4-Phenylenebis(methylene) selenocyanateOrganic selenium-containing compoundsLNCaP, C4-2NANANicole et al. (2010)
 Methylseleninic acid (MSeA)Organic selenium-containing compoundsLNCaP, LAPC-4TranscriptionInhibition of Sp1Husbeck et al. (2006)
 SeleniteNonorganic selenium-containing compoundsLNCaP, LAPC-4TranscriptionInhibition of Sp1Husbeck et al. (2006)
Hormones and vitamins
 AndrogenAndrogenLNCaPTranscriptionNABrinkmann et al. (1989)
 DHTAndrogenLNCaP+TranscriptionActivation of MycLee et al. (2009)
 R1881Synthetic androgenLNCaPTranscriptionNARavenna et al. (1995)
 Hydroxy-flutamide (OH-FLU)Anti-androgenLNCaPTranscriptionNARavenna et al. (1995)
 Fulvestrant (ICI 182 780)Anti-estrogenLNCaPTranscriptionNABhattacharyya et al. (2006)
 1,1-bis(3′-indolyl)-1-(p-substitutedphenyl) methanes (C-DIMs)PPARγ agonistsLNCaPTranscriptionPPARγ-independent pathwayChintharlapalli et al. (2007)
 9-cis retinoic acidRetinoic acidLNCaP+TranscriptionNAZhao et al. (1999)
 1α,25-Dihydroxyvitamin D3VitaminLNCaP+TranscriptionNAZhao et al. (1999)
 α-Tocopheryl succinate (vitamin E  succinate, VES)VitaminLNCaPTranscriptionInhibition of Sp1Huang et al. (2009)
 TS-1 (derivative of VES)VitaminLNCaPTranscriptionInhibition of Sp1Huang et al. (2009)
Signal transduction
 cAMPSignal transductionLNCaP+TranscriptionActivation of CREBMizokami et al. (1994)
 A23187Calcium ionophoreLNCaPTranscriptionProtein kinase C- or calmodulin-dependent pathwaysGong et al. (1995)
 ThapsigarginIntracellular endoplasmic reticulum Ca(2+)-ATPase inhibitorLNCaPTranscriptionProtein kinase C- or calmodulin-dependent pathwaysGong et al. (1995)
 Thapsigargin and its analoguesIntracellular endoplasmic reticulum Ca(2+)-ATPase inhibitorLNCaP, LAPC-4, VCaP, MDA-Pca-2b, 22Rv1TranslationNAVander Griend et al. (2009)
 CelecoxibCOX2 inhibitorLNCaPTranscriptionActivation of c-JunPan et al. (2003)
 NimesulideCOX2 inhibitorLNCaPTranscriptionActivation of c-JunPan et al. (2003)
 Sulindac sulfideNon-steroidal anti-inflammatory drugLNCaPTranscriptionActivation of c-Jun, inhibition of Sp1, NF1 and CREBLim et al. (2003)
 Sulindac sulfone (exisulind)Non-steroidal anti-inflammatory drugLNCaPTranscriptionActivation of c-Jun, inhibition of Sp1, NF1 and CREBLim et al. (2003)
 CP248Potent analogs of exisulindLNCaPTranscriptionActivation of c-Jun, inhibition of Sp1, NF1 and CREBLim et al. (2003)
 CP461Potent analogs of exisulindLNCaPTranscriptionActivation of c-Jun, inhibition of Sp1, NF1 and CREBLim et al. (2003)
 Trichostatin A (TSA)HDAC inhibitorAI-LNCaPTranscriptionRestoring suppressor element (ARS)-binding complexWang et al. (2004)
 Trichostatin A (TSA)HDAC inhibitorLNCaPTranscriptionNARokhlin et al. (2006)
 Suberohydroxamic acidHDAC inhibitorLNCaPTranscription?NARokhlin et al. (2006)
 DepsipeptideHDAC inhibitorLNCaPTranscription?NARokhlin et al. (2006)
 Sodium butyrateHDAC inhibitorLNCaPTranscription?NARokhlin et al. (2006)
 Sodium butyrateHDAC inhibitorLNCaP+NANAKim et al. (2007)
 Suberoylanilide hydroxamic acid (SAHA,   vorinostat)HDAC inhibitorLNCaPTranscriptionNAMarrocco et al. (2007)
 ParthenolideNFκB inhibitorLNCaP, 22Rv1TranscriptionInhibition of NFκBZhang et al. (2009)
 AZ10397767aCXC-chemokine receptor-2 inhibitorLNCaPTranscriptionInhibition of IL8 receptorSeaton et al. (2008)
 BAY11-7082aNFκB inhibitorLNCaPTranscriptionInhibition of NFκB induced by IL8Seaton et al. (2008)
 JNK inhibitor IaJNK inhibitorLNCaPTranscriptionInhibition of AP-1Seaton et al. (2008)
Others
 DoxorubicinAnticancer drug (anthracyclin)LNCaPNANARokhlin et al. (2006)
 EtoposideAnticancer drug (topoisomerase II inhibitor)LNCaPTranscriptionNALiu & Yamauchi (2010)
 Anti-β2-microglobulin polyclonal antibodyAntibodyLNCaP, C4-2TranscriptionNAHuang et al. (2008)
 Anti-β2-microglobulin monoclonal antibodyAntibodyLNCaP, C4-2TranscriptionInhibition of SREBP-1Huang et al. (2010)
 ResveratolPhytoalexinLNCaPTranscriptionNAMitchell et al. (1999)
 NigerincanAntibioticLNCaP, 22Rv1TranscriptionNAMashima et al. (2010)
 Clioquinol (CQ)Therapeutic agent for Alzheimer's diseaseLNCaP, C4-2NANAChen et al. (2007)
 Dibenzoylmethaneβ3-DiketoneLNCaPTranscriptionNAJackson et al. (2007)
 Functional domain of saposin CNeurotrophic peptideLNCaP+TranscriptionNADing et al. (2007)
 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazoleTriazole derivativeLNCaPTranscriptionNALoiarro et al. (2011)

NA, not available.

When IL8 was added to serum-free media; +/−, up/downregulation of androgen receptor.

Transcriptional regulation

Transcriptional control is thought to play a key role in the expression of a wide variety of genes, including AR. Transcription factors bind to DNA in a sequence-specific manner for each transcription factor, and positively or negatively affect gene expression through the control of transcription. The human AR is encoded by a single copy gene located on the X-chromosome. Two major mRNAs of 11 and 7.5 kb are transcribed from this gene, regulated by cis-acting elements in its promoter region. The human AR promoter region lacks a TATA-box and a CCAAT-box, and the binding sites for several transcription factors have been mapped (Tilley et al. 1990, Faber et al. 1991, 1993, Mizokami et al. 1994, Takane & McPhaul 1996). Several transcription factors have been reported to be responsible for controlling AR transcription. We discuss the relevance of these individual transcription factors in regulating AR expression, and in PCa.

cAMP response element-binding

cAMP response element-binding (CREB) is a transcription factor that binds to the cAMP response element (CRE, 5′-TGACGTGA-3′), thereby increasing or decreasing the transcription of its target genes. Several lines of evidence suggest that CREB is a proto-oncogene (Siu & Jin 2007).

Mizokami et al. (1994) isolated a 2.3-kb AR gene promoter region and analyzed it using a chloramphenicol acetyltransferase (CAT) assay. They found that the CRE was located between −530 and −380 bp from the transcription start site (TSS), and that AR transcription was increased by cAMP. They therefore suggested that the CREB transcription factor positively regulated AR transcription, although these results need to be confirmed using modern techniques.

The active form of phosphorylated CREB has been reported to be significantly increased in bone metastatic PCa. In addition, a PCa progression model demonstrating epithelial–mesenchymal transition (EMT) also showed an increase of CREB phosphorylation associated with progression (Wu et al. 2007), and CREB-regulated transcription has recently been reported to induce neuroendocrine-like differentiation (Deng et al. 2008). Thus, CREB may promote the pathogenesis of PCa through controlling the expression of AR and other target genes.

Myc

The Myc gene, located on chromosome 8, encodes a transcription factor that regulates the expression of its target genes by binding to an enhancer sequence (E-box, 5′-CAC(A/G)TG-3′) (Adhikary & Eilers 2005). Mutated Myc genes that are persistently expressed are found in many cancers, resulting in the aberrant expression of many genes involved in cell proliferation, and subsequent cancer formation; t(8;14) is a common translocation that is involved in the development of Burkitt's lymphoma (Boxer & Dang 2001). In contrast, numerous studies have demonstrated that inhibition of Myc leads to growth retardation and cell death in many cancers, making it a potential target for anti-cancer drugs (Hermeking 2003).

Myc has been found to be involved in AR transcriptional expression. Using a reporter gene assay in AR-nonexpressing PC-3 cells, Grad et al. (1999) showed that Myc positively regulated AR transcription by binding to the E-box region. This finding was supported by the results of a study indicating that the introduction of a mutation into the E-box in the AR promoter region decreased its transcription, as measured by CAT assay (Takane & McPhaul 1996). Recently, in a more definitive manner, Myc was proven to regulate AR transcription in LNCaP cells that express AR, and are the standard cell line used as a model for androgen-dependent PCa (Lee et al. 2009).

Myc is a well-known proto-oncogene, and many associations between Myc and oncogenesis have been reported in PCa. Elevated Myc expression in primary prostate tumors was recently reported to be a predictor of biochemical recurrence after radical prostatectomy (Hawksworth et al. 2010), which is consistent with the finding that higher AR expression is a predictor of poor outcome in patients treated with radical prostatectomy (Li et al. 2004, Rosner et al. 2007). Similarly, a recent study found that increased Myc gene copy number correlated with higher Gleason score (Chen et al. 2010), while Myc overexpression reduced the expression of the tumor-suppressor gene Nkx3.1 and induced prostate cellular transformation in a mouse model (Iwata et al. 2010).

c-Jun

c-Jun is a member of the activator protein-1 (AP-1) transcription complex, which is a heterodimeric protein composed of proteins belonging to the c-Fos, c-Jun, ATF, and JDP families. AP-1 upregulates the transcription of genes containing the tetradecanoylphorbol 13-acetate-responsive element (TRE; 5′-TGA(G/C)TCA-3′) (Hess et al. 2004), and regulates gene expression in response to a variety of stimuli, including cytokines, growth factors, stresses, and infections (Hess et al. 2004). AP-1 in turn controls a number of cellular processes, including differentiation, proliferation, and apoptosis (Ameyar et al. 2003).

c-Jun was reported to suppress AR transcription in a reporter gene assay using the AR promoter region in LNCaP cells (Pan et al. 2003). Similarly, the same group used a gel-shift assay to show that c-Jun bound to the TRE in the AR promoter region and repressed AR transcription (Yuan et al. 2004).

Although c-Jun is known to suppress AR expression, it also functions as an AR coactivator (Bubulya et al. 2000, Chen et al. 2006). Consistent with this notion, c-Jun is highly expressed in PCa tissues, compared with benign prostate hypertrophy tissues (Tiniakos et al. 2006). Similarly, patients with high expression levels of the active form of phosphorylated c-Jun had significantly shorter relapse-free survival times, compared with patients with low phosphorylated c-Jun protein expression, suggesting that increased active-c-Jun levels may promote castration-resistant tumor growth (Edwards et al. 2004). c-Jun suppression using antisense RNA strongly compromised the androgen-dependent proliferation of LNCaP cells (Chen et al. 2006). Overall, these findings suggest that c-Jun may be more involved in promoting AR function than in suppressing AR expression.

Sp1

Sp1 is a member of the Sp/KLF family of transcription factors that is involved in early development. Sp1 contains a zinc-finger protein motif, by which it binds directly to the consensus sequence 5′-(G/T)GGGCGG(G/A)(G/A)(C/T)-3′ (GC-box) and enhances gene transcription (Black et al. 2001).

In 1993, Faber et al. characterized the AR promoter region and identified a short GC-box (−59/−32 bp from TSS) and a long homopurine stretch (−117/−60 bp from TSS). They also implicated Sp1 in the control of AR transcription using a gene reporter assay and footprint analysis (Faber et al. 1993). These results were supported by a study demonstrating that the introduction of a mutation into the GC-box in the AR promoter region decreased AR transcription, as measured by CAT assay (Takane & McPhaul 1996). This finding was recently confirmed using LNCaP cells, showing that Sp1 overexpression increased AR transcription (Yuan et al. 2005). However, although a relationship between Sp1 and AR has been demonstrated, to the best of our knowledge, there have been no reports concerning the role of Sp1 in PCa.

p53

p53 is encoded by the TP53 gene, and is a tumor suppressor protein and transcription factor that binds to the p53-specific sequence (5′-(A/G)(A/G)(A/G)C(A/T)(T/A)G(T/C)(T/C)(T/C)-3′ (Matlashewski et al. 1984, Isobe et al. 1986, McBride et al. 1986, Kern et al. 1991). p53 is important in multicellular organisms, where it regulates the cell cycle, cellular apoptosis, and DNA repair, and functions as a tumor suppressor. As such, p53 has been described as ‘the guardian of the genome’, referring to its role in preventing genome mutation.

Forced p53 expression in LNCaP cells reduced AR transcription, while conversely, p53 knockdown increased AR transcription by binding to the p53 DNA-binding consensus sequence in the AR promoter region (−488/−469 bp from TSS; Alimirah et al. 2007).

Numerous studies concerning p53 have been performed in PCa and other solid cancers, and have suggested that mutations in the TP53 gene are associated with PCa progression (Navone et al. 1993, Bauer et al. 1995, Heidenberg et al. 1995, Nesslinger et al. 2003). Moreover, TP53 mutations may be an indicator of poor prognosis in PCa (Bauer et al. 1995, Heidenberg et al. 1995). Consistent with the above observations, it is interesting to note that the majority of metastatic PCa-derived cell lines harbor TP53 and/or AR mutations (Sobel & Sadar 2005). These observations suggest an important functional relationship between p53 and AR in the progression of PCa.

Foxo3a

Foxo3a belongs to the subclass ‘O’ of the forkhead family of transcription factors. These are characterized by a distinct forkhead DNA-binding domain, and bind to the Foxo-response element (5′-TTGTTTAC-3′) (Durham et al. 1999, Furuyama et al. 2000). There are three other human Foxo family members: Foxo1, Foxo4, and Foxo6. Foxo3a likely functions as a trigger for apoptosis through upregulation of pro-apoptotic proteins such as Bim and PUMA (Ekoff et al. 2007), or the downregulation of anti-apoptotic proteins such as FLIP (Skurk et al. 2004). Deregulation of Foxo3a is involved in tumorigenesis; for example, translocation of this gene with the MLL gene is associated with secondary acute leukemia (Myatt & Lam 2007), and Foxo3a is thus known as a tumor suppressor.

Chang and colleagues reported that Foxo3a positively regulated AR transcription by binding to the Foxo-response element in the AR promoter region (−1297/−1290 bp from TSS), and demonstrated a preventative role for the AR in the apoptosis of LNCaP cells by inhibition of the phosphoinositide 3-kinase/Akt signaling pathway (Yang et al. 2005).

The Foxo3a protein is the most highly expressed Foxo family member in PCa cells. It is hyperphosphorylated and markedly reduced in CRPC cells compared with androgen-dependent PCa cells (Lynch et al. 2005). Thus, Foxo function is compromised in CRPC cells, which appears to be incompatible with the observation that AR is frequently overexpressed in CRPC, but is consistent with its function in promoting apoptosis.

Lymphoid enhancer-binding factor 1

Lymphoid enhancer-binding factor 1 (LEF1) is the nuclear transducer of the activated-Wnt pathway. It binds to the LEF/TCF-binding site, 5′-(A/T)(A/T)CAAG-3′, and regulates the expression of its target genes (Roose & Clevers 1999). The Wnt-1/β-catenin/LEF1 pathway has been implicated in AR transcription, and Wnt-1 signaling leads to activation of the LEF1 complex and increased AR transcription (Yang et al. 2006). Moreover, LEF1 also positively regulates AR transcription by binding directly to LEF/TCF-binding sites (between −2000 and +0 bp from TSS), and was shown by microarray analysis to be upregulated in CRPC cells (Li et al. 2009).

Many studies have indicated a functional link between Wnt signaling and PCa (Yardy & Brewster 2005, Verras & Sun 2006), and intriguingly, a specific protein–protein interaction between β-catenin and AR resulting in AR transactivation has been demonstrated (Yang et al. 2002). Levels of both Wnt-1 and β-catenin were low in normal prostate cells, but were highly expressed in PCa cells. Increased Wnt-1 and β-catenin expression levels were also directly related to the Gleason score and to serum prostate-specific antigen (PSA) levels in PCa patients (Chen et al. 2004a,b). In addition, many studies have reported abnormal expression and mutation of β-catenin in PCa and in other solid cancers (Yardy & Brewster 2005). Synchronous activation of K-ras and β-catenin significantly reduced survival in a mouse model, associated with accelerated tumorigenesis and the development of invasive carcinoma (Pearson et al. 2009). In addition, Wnt/β-catenin activation promoted PCa progression in another mouse model (Yu et al. 2010), and the small molecule inhibitor of Wnt/β-catenin signaling, PKF118–310, has recently been shown to inhibit the proliferation of PCa cells (Lu et al. 2009).

Purine-rich element-binding protein α

Purine-rich element-binding protein α (PURα) is a nuclear protein with the ability to specifically bind to a purine-rich element found in single-stranded DNA (Bergemann & Johnson 1992, Bergemann et al. 1992). PURα binds to both DNA and RNA, and is believed to be involved in diverse functions, including DNA replication, gene transcription, mRNA translation, and RNA transport (Gallia et al. 2000). Several studies have indicated a role for PURα in the regulation of cell growth (Chang et al. 1996, Itoh et al. 1998, Stacey et al. 1999, Gallia et al. 2000, Barr & Johnson 2001, Darbinian et al. 2001, Lezon-Geyda et al. 2001).

Ferrari's group reported that AR transcription was inhibited by a novel transcriptional complex containing PURα and heterogeneous nuclear ribonucleoprotein-K (hnRNP-K), through binding to a specific sequence (repressor element) in the AR gene 5′-untranslated region. Furthermore, PURα expression was decreased in CRPC cells and tissues, implicating it in the pathogenesis of CRPC (Wang et al. 2008).

PURα expression is attenuated in CRPC cells compared with androgen-dependent PCa cells (Inoue et al. 2008). Recent studies demonstrated that overexpression of PURα in PC-3 and DU145 cells repressed their proliferation in vitro (Wang et al. 2008). Intriguingly, PURα has been shown to interact with several cellular regulatory proteins, including the E2F-1 and hypophosphorylated form of retinoblastoma protein (pRb; Johnson et al. 1995, Darbinian et al. 1999), both of which have been implicated in PCa progression (Yeh et al. 1998, Davis et al. 2006).

NFκB

NFκB (p65) is a protein complex that controls the transcription of various target genes, and is involved in cellular responses to stimuli such as stresses, cytokines, and infections (Gilmore 1999, 2006, Tian & Brasier 2003, Brasier 2006, Perkins 2007). NFκB regulates the expression of genes controlling cell proliferation and survival. Aberrant activation of NFκB is frequently seen in many cancers, and induces the expression of genes promoting cell proliferation and protecting against apoptosis. Conversely, defects in NFκB result in suppression of cell growth and increased susceptibility to apoptosis, leading to increased cell death. NFκB inhibition can suppress tumor growth, induce apoptosis, and sensitize cells to anti-cancer agents in various cancers.

NFκB was recently found to positively regulate AR transcription and cell growth in PCa cells (Zhang et al. 2009), though it was previously shown to act as a negative regulator of AR transcription in rat hepatic cells (Supakar et al. 1995). Furthermore, the inhibitor of NFκB has shown antitumor activity, even in CRPC cells. The results of another study using rat Sertoli cells support the positive regulation of AR expression by NFκB (Zhang et al. 2004).

Several studies have examined the expression of NFκB in PCa, and its relationship to clinical features. NFκB was overexpressed in prostatic intraepithelial neoplasia and PCa compared with benign epithelium (Sweeney et al. 2004), and recent studies found that NFκB expression was predictive of biochemical recurrence in patients with positive surgical margins after radical prostatectomy (Ismail et al. 2004). Nuclear localization of NFκB is increased in PCa with lymph node metastasis (Ismail et al. 2004), and can be used to predict patient outcome (Lessard et al. 2003). These results suggest that NFκB is frequently activated in PCa, and that its expression may be related to progression. NFκB is constitutively activated in CRPC xenografts where AR expression is also upregulated, suggesting a positive correlation between NFκB and AR expression (Chen & Sawyers 2002, Chen et al. 2004a,b).

Twist1

Twist1 belongs to the family of basic helix–loop–helix transcription factors that binds to the E-box sequence (5′-CANNTG-3′), and has been proposed to be an oncogene (Olson & Klein 1994, Maestro et al. 1999). Gene profiling analyses revealed that upregulation of Twist1 was associated with malignant transformation (van Doorn et al. 2004, Hoek et al. 2004). In addition, increased Twist1 expression has been detected in various malignant tumors compared with its expression in nonmalignant tissues (Maestro et al. 1999, Rosivatz et al. 2002), and was correlated with poorer outcome and shorter survival (Hoek et al. 2004). Recent evidence has also implicated Twist1 as a key factor responsible for metastasis (Yang et al. 2004).

We recently showed that Twist positively regulated AR expression in response to oxidative stress induced by androgen deprivation (Shiota et al. 2010). This finding is also supported by the study, similar to Myc (Takane & McPhaul 1996). Twist1 is a well-known master regulator of EMT, which may indicate a functional link between EMT and androgen/AR signaling.

Twist1 was upregulated in PCa with high Gleason score, and was involved in its colony forming and invasive abilities (Kwok et al. 2005). In another report, nuclear Twist expression was an important predictive factor for the metastatic potential of primary PCa (Yuen et al. 2007).

E2F/Rb

The E2F family of transcription factors consists of nine members, all of which bind to the E2F-binding site (5′-TTTCGCGC-3′) in the target promoter sequence. Three of them are activators: E2F-1, E2F-2, and E2F-3a, while the remaining six, E2F-3b and E2F-4–8, act as suppressors. The tumor suppressor protein pRb binds to E2F-1, and thus prevents its transcription-promoting activity. In the absence of pRb, E2F-1 transactivates its target genes, which facilitate the G1/S transition phase and S-phase (Pardee et al. 2004).

E2F-1 was shown to negatively regulate AR transcription in LNCaP cells (Davis et al. 2006). In this study, E2F-1 expression was elevated during prostate carcinogenesis and PCa progression, while AR expression was decreased in metastatic tissues from CRPC, in contrast to the results of many previous studies. Paradoxically, Knudsen's group recently reported that pRb knockdown with E2F-1 and E2F-3a overexpression cooperatively upregulated AR transcription in LNCaP cells (Sharma et al. 2010). In clinical samples, pRb and E2F-1 expression were negatively and positively correlated with AR expression, respectively. Furthermore, pRb expression in clinical samples was inversely correlated with the transition to CRPC.

Rb mutations have been linked to the development of PCa, and loss of heterozygosity of the Rb locus has been observed in clinical PCa samples (Ittmann & Wieczorek 1996). In a mouse model, pRb inactivation promoted prostate carcinogenesis and PCa progression (Maddison et al. 2004, Zhou et al. 2006). Intriguingly, fluorescence in situ hybridization analysis revealed that loss of the Rb gene was nearly four times more common after ADT than before therapy (22 vs 6%; Kaltz-Wittmer et al. 2000).

Sterol regulatory element-binding protein-1

Sterol regulatory element-binding proteins (SREBPs) are transcription factors that bind to the sterol regulatory element (5′-TCACNCCAC-3′). Mammalian SREBPs consist of SREBP-1 and SREBP-2, encoded by SREBF-1 and SREBF-2, respectively. SREBPs belong to the basic helix–loop–helix leucine zipper class of transcription factors (Yokoyama et al. 1993). Inactivated SREBPs are attached to the nuclear envelope and endoplasmic reticulum membranes. Decreased levels of sterols are associated with cleavage of SREBPs and translocation of the N-terminal domain to the nucleus. These activated SREBPs then bind to a specific sterol regulatory element, thus upregulating the synthesis of enzymes involved in sterol biosynthesis (Gasic 1994, Wang et al. 1994). Sterols in turn inhibit the cleavage of SREBPs, thus reducing the synthesis of additional sterols via negative feedback.

SREBP-1 was recently found to positively regulate AR transcription in LNCaP cells. SREBP-1 binding to the sterol regulatory element (−347/−336 bp from TSS) was demonstrated by gel-shift assay and chromatin-immunoprecipitation assay, while the regulation of AR transcription by SREBP-1 was proven by gene reporter assay using the AR promoter region (Huang et al. 2010).

SREBPs and their downstream effector genes have been found to be upregulated during progression to CRPC in the LNCaP xenograft model, as well as in clinical specimens of PCa (Ettinger et al. 2004). Intriguingly, 5-α reductase type 2 was also regulated by SREBPs in mouse prostate (Seo et al. 2009), and androgens and AR were found to reciprocally mediate SREBP-1 expression in PCa cells (Heemers et al. 2006, Ngan et al. 2009). This mutual regulation of SREBPs and androgen/AR signaling suggests a relationship between lipogenesis and PCa. In addition, pharmacologic inhibition of lipogenesis or RNA interference-mediated downregulation of key lipogenic genes induced apoptosis in cancer cell lines and reduced tumor growth in xenograft models. Lipogenesis is already seen in the earliest stages of prostate carcinogenesis, and increases with the development of CRPC (Swinnen et al. 2004).

Other factors

In addition to the transcription factors themselves, other molecules related to extracellular and intracellular signal transduction have also been implicated in AR transcription, through their regulation of known or unknown transcription factors (Table 1). Several of these factors have been reported to be involved in prostate carcinogenesis and PCa progression.

Clinical implications of targeting AR expression in PCa

As noted above, AR expression is regulated at the transcriptional level by several transcription factors, and various transcription factors are upregulated in PCa and CRPC, implicating them in the pathogenesis of these conditions. Suppression of AR expression is known to induce tumor regression in PCa, and even in CRPC (Chen et al. 2004a,b), and a strategy targeting AR expression may therefore be applicable to the treatment of PCa and CRPC. Indeed, the suppression of factors regulating AR expression using various methods, including RNA interference-mediated knockdown, small molecules, and antibodies, suppressed cell growth. The agents affecting AR transcription are listed in Table 2. In this list, a few inconsistencies among the reports were found. First, in androgen and synthetic androgen, R1881 had suppressive effect on AR expression at transcriptional level whereas Lee et al. reported dihydrotestosterone upregulated AR transcriptional level. Secondly, various histone deacetylase (HDAC) inhibitors downregulated AR expression in LNCaP cells although only Kim et al. (2007) reported that sodium butyrate upregulated AR expression. Although these inconsistencies might be derived from the differences of experimental condition, our data supported the result that androgen including dihydrotestosterone suppressed AR transcript (data not shown). Thus, androgen suppressed AR transcript whereas androgen is known to increase AR protein level by enhancing stability of AR protein (Gregory et al. 2001). This fact indicates that androgen functions not only as a ligand of the AR, but also as an AR stabilizer. Thus, androgen coordinately activates genomic and non-genomic AR downstream signaling.

These agents listed in Table 2 can be classified into several categories, according to their functions, and their therapeutic potentials are discussed below.

HDAC inhibitors have been intensively investigated as AR suppressors. Various HDAC inhibitors suppressed AR expression in LNCaP cells, supposedly at the transcriptional level, consistent with the results of many studies showing that HDAC inhibitors inhibited cell growth in PCa, and that HDAC was closely implicated in PCa progression (Abbas & Gupta 2008). So far, several HDAC inhibitors have been shown to exert anticancer effects in PCa using in vitro and in vivo models (Butler et al. 2000, Kuefer et al. 2004, Rephaeli et al. 2005, Kulp et al. 2006, Shabbeer et al. 2007, Sargeant et al. 2008, Hwang et al. 2010). Recently, a phase II trial using a HDAC inhibitor romidepsin was conducted in chemo-naïve patients with progressing and metastatic CRPC. However, the result was rather disappointing (Molife et al. 2010). Similarly, a phase II trial using another HDAC inhibitor vorinostat in advanced PCa patients progressing on prior chemotherapy showed an unsatisfactory result (Bradley et al. 2009). Also, the HDAC inhibitor, panobinostat, in CRPC patients exerted no remarkable efficiency in a phase I trial (Rathkopf et al. 2010). Thus, HDAC inhibitors seem to be less promising, at least in the treatment of CRPC.

Non-steroidal anti-inflammatory drugs (NSAIDs) have been available for many years and are widely used throughout the world. NSAIDs have also been proved to suppress AR transcription through modulation of transcription factors responsible for AR expression. Several preclinical studies have shown that NSAIDs inhibited PCa proliferation and induced cellular apoptosis in vitro and in vivo (Goluboff et al. 1999, Lim et al. 2003, Patel et al. 2005, Shigemura et al. 2005). Furthermore, several clinical trials have proven the efficiency of NSAIDs for the treatment of PCa. In a pilot study, the COX-2 inhibitor, celecoxib, reduced the rate of elevation of PSA after biochemical recurrence following radical prostatectomy and radiation therapy (Pruthi et al. 2004). This finding was proven by the following phase II trial (Pruthi et al. 2006). Similarly, sulindac sulfone (exisulind), a metabolite of the NSAID sulindac, also exerted a favorable effect on PSA recurrence after radical prostatectomy (Goluboff et al. 2001).

Selenium-containing compounds have also been extensively examined and have been found to suppress AR expression, probably at the transcriptional level. In vitro studies using androgen-dependent LNCaP and androgen-independent PC-3 cells have revealed that selenium could inhibit cell proliferation and induce apoptosis (Dong et al. 2003, Zhao et al. 2004). Also, in in vivo studies, selenium suppressed AR expression and growth of human PCa xenografts (Lee et al. 2006, Bhattacharyya et al. 2008). These findings are compatible with the results of a large-scale trial (Nutritional Prevention of Cancer (NPC) Trial; the Selenium and Vitamin E Chemoprevention Trial, SELECT), which indicated that selenium supplementation could reduce prostate carcinogenesis (Duffield-Lillico et al. 2003, Lippman et al. 2005). Because inorganic selenium compounds are known to produce genotoxic effects, organic selenium-containing compounds, which are better tolerated and exhibit anti-carcinogenic activity, seem to be more suitable for clinical usage.

Natural compounds, including polyphenols and natural resins, have also been investigated and found to reduce AR expression at both the transcriptional and post-transcriptional levels, with supposed tumor-suppressor roles in PCa. Many preclinical studies showed that various natural compounds exerted suppressive effects on PCa growth in vitro and in vivo. In addition, a phase II trial was conducted using phytochemicals in pomegranate juice for patients with recurrence after surgery or radiation for PCa, which showed that the PSA elevation rate was mitigated (Pantuck et al. 2006). Moreover, several chemicals that inhibit signaling pathways have also been reported, and show similar results to direct inhibition of their target molecules.

These and other agents under development that target AR expression have potential as chemopreventive compounds and therapeutic agents for PCa. Targeting AR expression at the transcriptional level, rather than directly targeting the AR itself through the use, e.g., of anti-androgens has several advantages. First, compounds targeting AR expression may exert additional effects on other targets implicated in tumor progression and suppression; indeed, some of the agents listed in Table 2 could affect the expression of various genes, such as cyclins and E2F, and signaling pathways, such as the Akt and mitogen-activated protein kinase pathways. Secondly, this strategy may be applicable to AR splice variants that are potentially refractory to anti-androgens, which bind to the ligand-binding domain of the AR, because splice variants may lack the ligand-binding domain and are thus active in the absence of ligand binding.

Conclusions and future directions

AR is known to contribute to prostate tumorigenesis and progression, as well as to the development of CRPC. This is supported by substantial evidence implicating the aberrant expression or improper regulation of AR in these disorders. Several factors, including transcription factors, regulate AR expression, and offer a feasible strategy for developing new therapeutic agents to treat both androgen-dependent PCa and CRPC. Recent research into AR splice variants has revealed the importance of developing AR-expression-targeting therapeutics able to regulate the expression of AR splice variants.

Further in vitro and in vivo studies, together with intelligently designed clinical trials, are needed to evaluate compounds suppressing AR expression for treatment of PCa and CRPC. Moreover, based on the findings obtained so far, novel therapeutic strategies and agents for treatment of PCa and CRPC through disruption of AR expression should be developed.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This work was supported by Health Sciences Research Grants for Clinical Research for Evidence Based Medicine and Grants-in-Aid for Cancer Research (016), from the Ministry of Health, Labour and Welfare, Japan; Kakenhi grants (22591769) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, Japan; Research Promotion Grant from the Japanese Foundation for Prostate Research, Japan; and Grant-in-Aid for Cancer Research from the Fukuoka Foundation for Sound Health, Japan.

Acknowledgements

We apologize to authors whose works were inadvertently overlooked or could not be cited because of space constraints. We thank Edanz Group Japan for editorial assistance.

References

  • Abbas A & Gupta S 2008 The role of histone deacetylases in prostate cancer. Epigenetics 3 300309.doi:10.4161/epi.3.6.7273.

  • Adam RM, Kim J, Lin J, Orsola A, Zhuang L, Rice DC & Freeman MR 2002 Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 143 45994608.doi:10.1210/en.2002-220561.

    • Search Google Scholar
    • Export Citation
  • Adhikary S & Eilers M 2005 Transcriptional regulation and transformation by Myc proteins. Nature Reviews. Molecular Cell Biology 6 635645.doi:10.1038/nrm1703.

    • Search Google Scholar
    • Export Citation
  • Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM & Choubey D 2007 Expression of androgen receptor is negatively regulated by p53. Neoplasia 9 11521159.doi:10.1593/neo.07769.

    • Search Google Scholar
    • Export Citation
  • Ameyar M, Wisniewska M & Weitzman JB 2003 A role for AP-1 in apoptosis: the case for and against. Biochimie 85 747752.doi:10.1016/j.biochi.2003.09.006.

    • Search Google Scholar
    • Export Citation
  • Barr SM & Johnson EM 2001 Ras-induced colony formation and anchorage-independent growth inhibited by elevated expression of Purα in NIH3T3 cells. Journal of Cellular Biochemistry 81 621638.doi:10.1002/jcb.1099.

    • Search Google Scholar
    • Export Citation
  • Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S & Moul JW 1995 p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clinical Cancer Research 1 12951300.

    • Search Google Scholar
    • Export Citation
  • Bergemann AD & Johnson EM 1992 The HeLa Pur factor binds single-stranded DNA at a specific element conserved in gene flanking regions and origins of DNA replication. Molecular and Cellular Biology 12 12571265.

    • Search Google Scholar
    • Export Citation
  • Bergemann AD, Ma ZW & Johnson EM 1992 Sequence of cDNA comprising the human pur gene and sequence-specific single-stranded-DNA-binding properties of the encoded protein. Molecular and Cellular Biology 12 56735682.

    • Search Google Scholar
    • Export Citation
  • Bhattacharyya RS, Krishnan AV, Swami S & Feldman D 2006 Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Molecular Cancer Therapeutics 5 15391549.doi:10.1158/1535-7163.MCT-06-0065.

    • Search Google Scholar
    • Export Citation
  • Bhattacharyya RS, Husbeck B, Feldman D & Knox SJ 2008 Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. International Journal of Radiation Oncology, Biology, Physics 72 935940.doi:10.1016/j.ijrobp.2008.07.005.

    • Search Google Scholar
    • Export Citation
  • Black AR, Black JD & Azizkhan-Clifford J 2001 Sp1 and Krüppel-like factor family of transcription factors in cell growth regulation and cancer. Journal of Cellular Physiology 188 143160.doi:10.1002/jcp.1111.

    • Search Google Scholar
    • Export Citation
  • Boxer LM & Dang CV 2001 Translocations involving c-myc and c-myc function. Oncogene 20 55955610.doi:10.1038/sj.onc.1204595.

  • Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H & Hussain M 2009 Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 115 55415549.doi:10.1002/cncr.24597.

    • Search Google Scholar
    • Export Citation
  • Brasier AR 2006 The NF-κB regulatory network. Cardiovascular Toxicology 6 111130.doi:10.1385/CT:6:2:111.

  • Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, van der Korput JA, Voorhorst MM, van Laar JH & Mulder E et al. 1989 The human androgen receptor: domain structure, genomic organization and regulation of expression. Journal of Steroid Biochemistry 34 307310.doi:10.1016/0022-4731(89)90098-8.

    • Search Google Scholar
    • Export Citation
  • Bubulya A, Zhou XF, Shen XQ, Fisher CJ & Shemshedini L 2000 c-Jun targets amino terminus of androgen receptor in regulating androgen-responsive transcription. Endocrine 13 5562.doi:10.1385/ENDO:13:1:55.

    • Search Google Scholar
    • Export Citation
  • Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA & Richon VM 2000 Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Research 60 51655170.

    • Search Google Scholar
    • Export Citation
  • Chang CF, Gallia GL, Muralidharan V, Chen NN, Zoltick P, Johnson E & Khalili K 1996 Evidence that replication of human neurotropic JC virus DNA in glial cells is regulated by the sequence-specific single-stranded DNA-binding protein Purα. Journal of Virology 70 41504156.

    • Search Google Scholar
    • Export Citation
  • Chen CD & Sawyers CL 2002 NF-κB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Molecular and Cellular Biology 22 28622870.doi:10.1128/MCB.22.8.2862-2870.2002.

    • Search Google Scholar
    • Export Citation
  • Chen S, Ruan Q, Bedner E, Deptala A, Wang X, Hsieh TC, Traganos F & Darzynkiewicz Z 2001 Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, cell cycle progression and apoptosis of prostate cancer cell lines. Cell Proliferation 34 293304.doi:10.1046/j.0960-7722.2001.00213.x.

    • Search Google Scholar
    • Export Citation
  • Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D & Rabbani SA 2004a Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101 13451356.doi:10.1002/cncr.20518.

    • Search Google Scholar
    • Export Citation
  • Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004b Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 3339.doi:10.1038/nm972.

    • Search Google Scholar
    • Export Citation
  • Chen SY, Cai C, Fisher CJ, Zheng Z, Omwancha J, Hsieh CL & Shemshedini L 2006 c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene 25 72127223.doi:10.1038/sj.onc.1209705.

    • Search Google Scholar
    • Export Citation
  • Chen D, Cui QC, Yang H, Barrea RA, Sarkar FH, Sheng S, Yan B, Reddy GP & Dou QP 2007 Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Research 67 16361644.doi:10.1158/0008-5472.CAN-06-3546.

    • Search Google Scholar
    • Export Citation
  • Chen H, Liu W, Roberts W, Hooker S, Fedor H, DeMarzo A, Isaacs W & Kittles RA 2010 8q24 allelic imbalance and MYC gene copy number in primary prostate cancer. Prostate Cancer and Prostatic Diseases 13 238243.doi:10.1038/pcan.2010.20.

    • Search Google Scholar
    • Export Citation
  • Chintharlapalli S, Papineni S & Safe S 2007 1,1-bis(3′-indolyl)-1-(p-substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor gamma-independent pathways. Molecular Pharmacology 71 558569.doi:10.1124/mol.106.028696.

    • Search Google Scholar
    • Export Citation
  • Chiu FL & Lin JK 2008 Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate 68 6171.doi:10.1002/pros.20690.

    • Search Google Scholar
    • Export Citation
  • Chun JY, Nadiminty N, Lee SO, Onate SA, Lou W & Gao AC 2006 Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. Molecular Cancer Therapeutics 5 913918.doi:10.1158/1535-7163.MCT-05-0389.

    • Search Google Scholar
    • Export Citation
  • Darbinian N, Gallia GL, Kundu M, Shcherbik N, Tretiakova A, Giordano A & Khalili K 1999 Association of Purα and E2F-1 suppresses transcriptional activity of E2F-1. Oncogene 18 63986402.doi:10.1038/sj.onc.1203011.

    • Search Google Scholar
    • Export Citation
  • Darbinian N, Gallia GL, King J, Del Valle L, Johnson EM & Khalili K 2001 Growth inhibition of glioblastoma cells by human Purα. Journal of Cellular Physiology 189 334340.doi:10.1002/jcp.10029.

    • Search Google Scholar
    • Export Citation
  • Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA & Day M 2006 Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Research 66 1189711906.doi:10.1158/0008-5472.CAN-06-2497.

    • Search Google Scholar
    • Export Citation
  • Debes JD & Tindall DJ 2004 Mechanisms of androgen-refractory prostate cancer. New England Journal of Medicine 351 14881490.doi:10.1056/NEJMp048178.

    • Search Google Scholar
    • Export Citation
  • Dehm SM, Schmidt LJ, Heemers HV, Vessella RL & Tindall DJ 2008 Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Research 68 54695477.doi:10.1158/0008-5472.CAN-08-0594.

    • Search Google Scholar
    • Export Citation
  • Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ & Hu CD 2008 Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Research 68 96639670.doi:10.1158/0008-5472.CAN-08-2229.

    • Search Google Scholar
    • Export Citation
  • Ding Y, Yuan HQ, Kong F, Hu XY, Ren K, Cai J, Wang XL & Young CY 2007 Ectopic expression of neurotrophic peptide derived from saposin C increases proliferation and upregulates androgen receptor expression and transcriptional activity in human prostate cancer cells. Asian Journal of Andrology 9 601609.doi:10.1111/j.1745-7262.2007.00328.x.

    • Search Google Scholar
    • Export Citation
  • Dong Y, Zhang H, Hawthorn L, Ganther HE & Ip C 2003 Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Research 63 5259.

    • Search Google Scholar
    • Export Citation
  • van Doorn R, Dijkman R, Vermeer MH, Out-Luiting JJ, van der Raaij-Helmer EM, Willemze R & Tensen CP 2004 Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Research 64 55785586.doi:10.1158/0008-5472.CAN-04-1253.

    • Search Google Scholar
    • Export Citation
  • Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC & Nutritional Prevention of Cancer Study Group 2003 Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU International 91 608612.doi:10.1046/j.1464-410X.2003.04167.x.

    • Search Google Scholar
    • Export Citation
  • Durham SK, Suwanichkul A, Scheimann AO, Yee D, Jackson JG, Barr FG & Powell DR 1999 FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter. Endocrinology 140 31403146.doi:10.1210/en.140.7.3140.

    • Search Google Scholar
    • Export Citation
  • Edwards J, Krishna NS, Mukherjee R & Bartlett JM 2004 The role of c-Jun and c-Fos expression in androgen-independent prostate cancer. Journal of Pathology 204 153158.doi:10.1002/path.1605.

    • Search Google Scholar
    • Export Citation
  • Ekoff M, Kaufmann T, Engström M, Motoyama N, Villunger A, Jönsson JI, Strasser A & Nilsson G 2007 The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood 110 32093217.doi:10.1182/blood-2007-02-073957.

    • Search Google Scholar
    • Export Citation
  • Emami KH, Brown LG, Pitts TE, Sun X, Vessella RL & Corey E 2009 Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate 69 14811492.doi:10.1002/pros.20998.

    • Search Google Scholar
    • Export Citation
  • Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME & Nelson CC 2004 Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Research 64 22122221.doi:10.1158/0008-5472.CAN-2148-2.

    • Search Google Scholar
    • Export Citation
  • Faber PW, van Rooij HC, van der Korput HA, Baarends WM, Brinkmann AO, Grootegoed JA & Trapman J 1991 Characterization of the human androgen receptor transcription unit. Journal of Biological Chemistry 266 1074310749.

    • Search Google Scholar
    • Export Citation
  • Faber PW, van Rooij HC, Schipper HJ, Brinkmann AO & Trapman J 1993 Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. Journal of Biological Chemistry 268 92969301.

    • Search Google Scholar
    • Export Citation
  • Furuyama T, Nakazawa T, Nakano I & Mori N 2000 Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochemical Journal 349 629634.doi:10.1042/0264-6021:3490629.

    • Search Google Scholar
    • Export Citation
  • Gallia GL, Johnson EM & Khalili K 2000 Purα: a multifunctional single-stranded DNA- and RNA-binding protein. Nucleic Acids Research 28 31973205.doi:10.1093/nar/28.17.3197.

    • Search Google Scholar
    • Export Citation
  • Gasic GP 1994 Basic-helix–loop–helix transcription factor and sterol sensor in a single membrane-bound molecule. Cell 77 1719.doi:10.1016/0092-8674(94)90230-5.

    • Search Google Scholar
    • Export Citation
  • Gilmore TD 1999 The Rel/NF-κB signal transduction pathway: introduction. Oncogene 18 68426844.doi:10.1038/sj.onc.1203237.

  • Gilmore TD 2006 Introduction to NF-κB: players, pathways, perspectives. Oncogene 25 66806684.doi:10.1038/sj.onc.1209954.

  • Goluboff ET, Shabsigh A, Saidi JA, Weinstein IB, Mitra N, Heitjan D, Piazza GA, Pamukcu R, Buttyan R & Olsson CA 1999 Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53 440445.doi:10.1016/S0090-4295(98)00513-5.

    • Search Google Scholar
    • Export Citation
  • Goluboff ET, Prager D, Rukstalis D, Giantonio B, Madorsky M, Barken I, Weinstein IB, Partin AW, Olsson CA & UCLA Oncology Research Network 2001 Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. Journal of Urology 166 882886.doi:10.1016/S0022-5347(05)65856-9.

    • Search Google Scholar
    • Export Citation
  • Gong Y, Blok LJ, Perry JE, Lindzey JK & Tindall DJ 1995 Calcium regulation of androgen receptor expression in the human prostate cancer cell line LNCaP. Endocrinology 136 21722178.doi:10.1210/en.136.5.2172.

    • Search Google Scholar
    • Export Citation
  • Grad JM, Dai JL, Wu S & Burnstein KL 1999 Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Molecular Endocrinology 13 18961911.doi:10.1210/me.13.11.1896.

    • Search Google Scholar
    • Export Citation
  • Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL & French FS 1998 Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Research 58 57185724.

    • Search Google Scholar
    • Export Citation
  • Gregory CW, Johnson RT Jr, Mohler JL, French FS & Wilson EM 2001 Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Research 61 28922898.

    • Search Google Scholar
    • Export Citation
  • Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J & Tepper CG et al. 2009 A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research 69 23052313.doi:10.1158/0008-5472.CAN-08-3795.

    • Search Google Scholar
    • Export Citation
  • Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S & Petrovics G 2010 Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer and Prostatic Diseases 13 311315.doi:10.1038/pcan.2010.31.

    • Search Google Scholar
    • Export Citation
  • He ML, Yuan HQ, Jiang AL, Gong AY, Chen WW, Zhang PJ, Young CY & Zhang JY 2006 Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells. Cancer 106 25472555.doi:10.1002/cncr.21935.

    • Search Google Scholar
    • Export Citation
  • Heemers HV, Verhoeven G & Swinnen JV 2006 Androgen activation of the sterol regulatory element-binding protein pathway: current insights. Molecular Endocrinology 20 22652277.doi:10.1210/me.2005-0479.

    • Search Google Scholar
    • Export Citation
  • Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW & Srivastava S 1995 Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. Journal of Urology 154 414421.doi:10.1016/S0022-5347(01)67065-4.

    • Search Google Scholar
    • Export Citation
  • Hermeking H 2003 The MYC oncogene as a cancer drug target. Current Cancer Drug Targets 3 163175.doi:10.2174/1568009033481949.

  • Hess J, Angel P & Schorpp-Kistner M 2004 AP-1 subunits: quarrel and harmony among siblings. Journal of Cell Science 117 59655973.doi:10.1242/jcs.01589.

    • Search Google Scholar
    • Export Citation
  • Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E & Trombetta ES et al. 2004 Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Research 64 52705282.doi:10.1158/0008-5472.CAN-04-0731.

    • Search Google Scholar
    • Export Citation
  • Hoshino K, Ishiguro H, Teranishi JI, Yoshida SI, Umemura S, Kubota Y & Uemura H 2010 Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. Prostate 71 964975.doi:10.1002/pros.21312.

    • Search Google Scholar
    • Export Citation
  • Hsu JC, Zhang J, Dev A, Wing A, Bjeldanes LF & Firestone GL 2005 Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells. Carcinogenesis 26 18961904.doi:10.1093/carcin/bgi155.

    • Search Google Scholar
    • Export Citation
  • Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL & Isaacs WB et al. 2009 Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Research 69 1622.doi:10.1158/0008-5472.CAN-08-2764.

    • Search Google Scholar
    • Export Citation
  • Huang WC, Havel JJ, Zhau HE, Qian WP, Lue HW, Chu CY, Nomura T & Chung LW 2008 β2-Microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clinical Cancer Research 14 53415347.doi:10.1158/1078-0432.CCR-08-0793.

    • Search Google Scholar
    • Export Citation
  • Huang PH, Wang D, Chuang HC, Wei S, Kulp SK & Chen CS 2009 α-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis 30 11251131.doi:10.1093/carcin/bgp112.

    • Search Google Scholar
    • Export Citation
  • Huang WC, Zhau HE & Chung LW 2010 Androgen receptor survival signaling is blocked by anti-β2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. Journal of Biological Chemistry 285 79477956.doi:10.1074/jbc.M109.092759.

    • Search Google Scholar
    • Export Citation
  • Husbeck B, Bhattacharyya RS, Feldman D & Knox SJ 2006 Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Molecular Cancer Therapeutics 5 20782085.doi:10.1158/1535-7163.MCT-06-0056.

    • Search Google Scholar
    • Export Citation
  • Hwang JJ, Kim YS, Kim MJ, Kim DE, Jeong IG & Kim CS 2010 Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. Journal of Urology 184 25572564.doi:10.1016/j.juro.2010.07.035.

    • Search Google Scholar
    • Export Citation
  • Inoue T, Leman ES, Yeater DB & Getzenberg RH 2008 The potential role of purine-rich element binding protein (PUR) α as a novel treatment target for hormone-refractory prostate cancer. Prostate 68 10481056.doi:10.1002/pros.20764.

    • Search Google Scholar
    • Export Citation
  • Ismail HA, Lessard L, Mes-Masson AM & Saad F 2004 Expression of NfκB in prostate cancer lymph node metastases. Prostate 58 308313.doi:10.1002/pros.10335.

    • Search Google Scholar
    • Export Citation
  • Isobe M, Emanuel BS, Givol D, Oren M & Croce CM 1986 Localization of gene for human p53 tumour antigen to band 17p13. Nature 320 8485.doi:10.1038/320084a0.

    • Search Google Scholar
    • Export Citation
  • Itoh H, Wortman MJ, Kanovsky M, Uson RR, Gordon RE, Alfano N & Johnson EM 1998 Alterations in Purα levels and intracellular localization in the CV-1 cell cycle. Cell Growth and Differentiation 9 651665.

    • Search Google Scholar
    • Export Citation
  • Ittmann MM & Wieczorek R 1996 Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Human Pathology 27 2834.doi:10.1016/S0046-8177(96)90134-3.

    • Search Google Scholar
    • Export Citation
  • Iwata T, Schultz D, Hicks J, Hubbard GK, Mutton LN, Lotan TL, Bethel C, Lotz MT, Yegnasubramanian S & Nelson WG et al. 2010 MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS ONE 5 e9427 doi:10.1371/journal.pone.0009427.

    • Search Google Scholar
    • Export Citation
  • Jackson KM, Frazier MC & Harris WB 2007 Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer. Anticancer Research 27 14831488.

    • Search Google Scholar
    • Export Citation
  • Johnson EM, Chen PL, Krachmarov CP, Barr SM, Kanovsky M, Ma ZW & Lee WH 1995 Association of human Purα with the retinoblastoma protein, Rb, regulates binding to the single-stranded DNA Purα recognition element. Journal of Biological Chemistry 270 2435224360.doi:10.1074/jbc.270.41.24352.

    • Search Google Scholar
    • Export Citation
  • Kaltz-Wittmer C, Klenk U, Glaessgen A, Aust DE, Diebold J, Löhrs U & Baretton GB 2000 FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Laboratory Investigation 80 14551464.

    • Search Google Scholar
    • Export Citation
  • Kang HY, Huang HY, Hsieh CY, Li CF, Shyr CR, Tsai MY, Chang C, Chuang YC & Huang KE 2009 Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer. Journal of Bone and Mineral Research 24 11801193.doi:10.1359/jbmr.090219.

    • Search Google Scholar
    • Export Citation
  • Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP & Reddy GP 2007 Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Research 67 77827788.doi:10.1158/0008-5472.CAN-07-1483.

    • Search Google Scholar
    • Export Citation
  • Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C & Vogelstein B 1991 Identification of p53 as a sequence-specific DNA-binding protein. Science 252 17081711.doi:10.1126/science.2047879.

    • Search Google Scholar
    • Export Citation
  • Kim J, Park H, Im JY, Choi WS & Kim HS 2007 Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells. Anticancer Research 27 32853292.

    • Search Google Scholar
    • Export Citation
  • Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, Hautmann RE & Gschwend JE 2004 Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. British Journal of Cancer 90 535541.doi:10.1038/sj.bjc.6601510.

    • Search Google Scholar
    • Export Citation
  • Kulp SK, Chen CS, Wang DS, Chen CY & Chen CS 2006 Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clinical Cancer Research 12 51995206.doi:10.1158/1078-0432.CCR-06-0429.

    • Search Google Scholar
    • Export Citation
  • Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL & Glackin C et al. 2005 Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Research 65 51535162.doi:10.1158/0008-5472.CAN-04-3785.

    • Search Google Scholar
    • Export Citation
  • Lee HH, Ho CT & Lin JK 2004 Theaflavin-3,3′-digallate and penta-O-galloyl-β-d-glucose inhibit rat liver microsomal 5α-reductase activity and the expression of androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 25 11091118.doi:10.1093/carcin/bgh106.

    • Search Google Scholar
    • Export Citation
  • Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y & Gao AC 2006 Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 66 10701075.doi:10.1002/pros.20329.

    • Search Google Scholar
    • Export Citation
  • Lee JG, Zheng R, McCafferty-Cepero JM, Burnstein KL, Nanus DM & Shen R 2009 Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. Molecular Carcinogenesis 48 141149.doi:10.1002/mc.20462.

    • Search Google Scholar
    • Export Citation
  • Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB & Saad F 2003 NF-κB nuclear localization and its prognostic significance in prostate cancer. BJU International 91 417420.doi:10.1046/j.1464-410X.2003.04104.x.

    • Search Google Scholar
    • Export Citation
  • Lezon-Geyda K, Najfeld V & Johnson EM 2001 Deletions of PURA, at 5q31, and PURB, at 7p13, in myelodysplastic syndrome and progression to acute myelogenous leukemia. Leukemia 15 954962.doi:10.1038/sj.leu.2402108.

    • Search Google Scholar
    • Export Citation
  • Li R, Wheeler T, Dai H, Frolov A, Thompson T & Ayala G 2004 High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. American Journal of Surgical Pathology 28 928934.doi:10.1097/00000478-200407000-00013.

    • Search Google Scholar
    • Export Citation
  • Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter R, Wei J, Peng Y, Zou X & Pellicer A et al. 2009 LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Research 69 33323338.doi:10.1158/0008-5472.CAN-08-3380.

    • Search Google Scholar
    • Export Citation
  • Lim JT, Piazza GA, Pamukcu R, Thompson WJ & Weinstein IB 2003 Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Clinical Cancer Research 9 49724982.

    • Search Google Scholar
    • Export Citation
  • Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL & Visakorpi T 2001 Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 61 35503555.

    • Search Google Scholar
    • Export Citation
  • Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, Santella RM, Probstfield JL, Moinpour CM & Albanes D et al. 2005 Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Journal of the National Cancer Institute 97 94102.doi:10.1093/jnci/dji009.

    • Search Google Scholar
    • Export Citation
  • Litvinov IV, De Marzo AM & Isaacs JT 2003 Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? Journal of Clinical Endocrinology and Metabolism 88 29722982.doi:10.1210/jc.2002-022038.

    • Search Google Scholar
    • Export Citation
  • Liu S & Yamauchi H 2010 Etoposide induces growth arrest and disrupts androgen receptor signaling in prostate cancer cells. Oncology Reports 23 165170.doi:10.3892/or_00000730.

    • Search Google Scholar
    • Export Citation
  • Loiarro M, Campo S, Arseni B, Rossi S, D'Alessio V, De Santis R, Sette C & Ruggiero V 2011 Anti-proliferative effect of a triazole derivative (ST1959) on LNCaP human prostate cancer cells through down-regulation of cyclin and androgen receptor expression. Prostate 71 3241.doi:10.1002/pros.21219.

    • Search Google Scholar
    • Export Citation
  • Lu W, Tinsley HN, Keeton A, Qu Z, Piazza GA & Li Y 2009 Suppression of Wnt/β-catenin signaling inhibits prostate cancer cell proliferation. European Journal of Pharmacology 602 814.doi:10.1016/j.ejphar.2008.10.053.

    • Search Google Scholar
    • Export Citation
  • Lynch RL, Konicek BW, McNulty AM, Hanna KR, Lewis JE, Neubauer BL & Graff JR 2005 The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Molecular Cancer Research 3 163169.doi:10.1158/1541-7786.MCR-04-0163.

    • Search Google Scholar
    • Export Citation
  • Maddison LA, Sutherland BW, Barrios RJ & Greenberg NM 2004 Conditional deletion of Rb causes early stage prostate cancer. Cancer Research 64 60186025.doi:10.1158/0008-5472.CAN-03-2509.

    • Search Google Scholar
    • Export Citation
  • Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH & Hannon GJ 1999 Twist is a potential oncogene that inhibits apoptosis. Genes and Development 13 22072217.doi:10.1101/gad.13.17.2207.

    • Search Google Scholar
    • Export Citation
  • Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM & Butler LM 2007 Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Molecular Cancer Therapeutics 6 5160.doi:10.1158/1535-7163.MCT-06-0144.

    • Search Google Scholar
    • Export Citation
  • Mashima T, Okabe S & Seimiya H 2010 Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth. Molecular Pharmacology 78 846854.doi:10.1124/mol.110.064790.

    • Search Google Scholar
    • Export Citation
  • Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L & Benchimol S 1984 Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO Journal 3 32573262.

    • Search Google Scholar
    • Export Citation
  • McBride OW, Merry D & Givol D 1986 The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). PNAS 83 130134.doi:10.1073/pnas.83.1.130.

    • Search Google Scholar
    • Export Citation
  • Mitchell SH, Zhu W & Young CY 1999 Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Research 59 58925895.

    • Search Google Scholar
    • Export Citation
  • Miyamoto H, Messing EM & Chang C 2004 Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61 332353.doi:10.1002/pros.20115.

    • Search Google Scholar
    • Export Citation
  • Mizokami A, Yeh SY & Chang C 1994 Identification of 3′,5′-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Molecular Endocrinology 8 7788.doi:10.1210/me.8.1.77.

    • Search Google Scholar
    • Export Citation
  • Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S, Riggs CE Jr, Higano C, Stadler WM & McCulloch W et al. 2010 Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Annals of Oncology 21 109113.doi:10.1093/annonc/mdp270.

    • Search Google Scholar
    • Export Citation
  • Myatt SS & Lam EW 2007 The emerging roles of forkhead box (Fox) proteins in cancer. Nature Reviews. Cancer 7 847859.doi:10.1038/nrc2223.

    • Search Google Scholar
    • Export Citation
  • Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nicholas WW, von Eschenbach AC & Conti CJ 1993 p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. Journal of the National Cancer Institute 85 16571669.doi:10.1093/jnci/85.20.1657.

    • Search Google Scholar
    • Export Citation
  • Nesslinger NJ, Shi XB & deVere White RW 2003 Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Research 63 22282233.

    • Search Google Scholar
    • Export Citation
  • Ngan S, Stronach EA, Photiou A, Waxman J, Ali S & Buluwela L 2009 Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene 28 20512063.doi:10.1038/onc.2009.68.

    • Search Google Scholar
    • Export Citation
  • Nicole DF, Karam E, Yuan-Wan S, John TP & Raghu S 2010 1,4-Phenylenebis(methylene)selenocyanate, but not selenomethionine, inhibits androgen receptor and Akt signaling in human prostate cancer cells. Cancer Prevention Research 3 975984.doi:10.1158/1940-6207.CAPR-10-0054.

    • Search Google Scholar
    • Export Citation
  • Olson EN & Klein WH 1994 bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. Genes and Development 8 18.doi:10.1101/gad.8.1.1.

    • Search Google Scholar
    • Export Citation
  • Pan Y, Zhang JS, Gazi MH & Young CY 2003 The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiology, Biomarkers and Prevention 12 769774.

    • Search Google Scholar
    • Export Citation
  • Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H & Elashoff R et al. 2006 Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clinical Cancer Research 12 40184026.doi:10.1158/1078-0432.CCR-05-2290.

    • Search Google Scholar
    • Export Citation
  • Pardee AB, Li CJ & Reddy GP 2004 Regulation in S phase by E2F. Cell Cycle 3 10911094.doi:10.4161/cc.3.9.1143.

  • Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT & Dannenberg AJ 2005 Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clinical Cancer Research 11 19992007.doi:10.1158/1078-0432.CCR-04-1877.

    • Search Google Scholar
    • Export Citation
  • Pearson HB, Phesse TJ & Clarke AR 2009 K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Research 69 94101.doi:10.1158/0008-5472.CAN-08-2895.

    • Search Google Scholar
    • Export Citation
  • Perkins ND 2007 Integrating cell-signalling pathways with NF-κB and IKK function. Nature Reviews. Molecular Cell Biology 8 4962.doi:10.1038/nrm2083.

    • Search Google Scholar
    • Export Citation
  • Pruthi RS, Derksen JE & Moore D 2004 A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU International 93 275278.doi:10.1111/j.1464-410X.2004.04601.x.

    • Search Google Scholar
    • Export Citation
  • Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C & Wallen E 2006 Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clinical Cancer Research 12 21722177.doi:10.1158/1078-0432.CCR-05-2067.

    • Search Google Scholar
    • Export Citation
  • Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM, Hu J, Dzik-Jurasz A, Yang W & Scher HI 2010 A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology 66 181189.doi:10.1007/s00280-010-1289-x.

    • Search Google Scholar
    • Export Citation
  • Ravenna L, Gulino A, Lubrano C, Sciarra F, Di Silverio F, D'Eramo G, Vacca A, Felli MP, Maroder M & Frati L et al. 1995 Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP. Prostate 26 290298.doi:10.1002/pros.2990260604.

    • Search Google Scholar
    • Export Citation
  • Ren F, Zhang S, Mitchell SH, Butler R & Young CY 2000 Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 19 19241932.doi:10.1038/sj.onc.1203511.

    • Search Google Scholar
    • Export Citation
  • Rephaeli A, Blank-Porat D, Tarasenko N, Entin-Meer M, Levovich I, Cutts SM, Phillips DR, Malik Z & Nudelman A 2005 In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. International Journal of Cancer 116 226235.doi:10.1002/ijc.21030.

    • Search Google Scholar
    • Export Citation
  • Rokhlin OW, Glover RB, Guseva NV, Taghiyev AF, Kohlgraf KG & Cohen MB 2006 Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Molecular Cancer Research 4 113123.doi:10.1158/1541-7786.MCR-05-0085.

    • Search Google Scholar
    • Export Citation
  • Roose J & Clevers H 1999 TCF transcription factors: molecular switches in carcinogenesis. Biochimica et Biophysica Acta 1424 M23M37.doi:10.1016/S0304-419X(99)00026-8.

    • Search Google Scholar
    • Export Citation
  • Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Höfler H & Becker KF 2002 Differential expression of the epithelial–mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. American Journal of Pathology 161 18811891.doi:10.1016/S0002-9440(10)64464-1.

    • Search Google Scholar
    • Export Citation
  • Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S & Petrovics G 2007 Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology 70 12251229.doi:10.1016/j.urology.2007.09.010.

    • Search Google Scholar
    • Export Citation
  • Roy-Burman P, Tindall DJ, Robins DM, Greenberg NM, Hendrix MJ, Mohla S, Getzenberg RH, Isaacs JT & Pienta KJ 2005 Androgens and prostate cancer: are the descriptors valid? Cancer Biology and Therapy 4 45.

    • Search Google Scholar
    • Export Citation
  • Sargeant AM, Rengel RC, Kulp SK, Klein RD, Clinton SK, Wang YC & Chen CS 2008 OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Research 68 39994009.doi:10.1158/0008-5472.CAN-08-0203.

    • Search Google Scholar
    • Export Citation
  • Scher HI & Sawyers CL 2005 Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of Clinical Oncology 23 82538261.doi:10.1200/JCO.2005.03.4777.

    • Search Google Scholar
    • Export Citation
  • Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG & Waugh DJ 2008 Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 29 11481156.doi:10.1093/carcin/bgn109.

    • Search Google Scholar
    • Export Citation
  • Seo YK, Zhu B, Jeon TI & Osborne TF 2009 Regulation of steroid 5-α reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin. Experimental Cell Research 315 31333139.doi:10.1016/j.yexcr.2009.05.025.

    • Search Google Scholar
    • Export Citation
  • Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R & Carducci MA 2007 Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67 10991110.doi:10.1002/pros.20587.

    • Search Google Scholar
    • Export Citation
  • Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE & Witkiewicz AK et al. 2010 The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. Journal of Clinical Investigation 120 44784492.doi:10.1172/JCI44239.

    • Search Google Scholar
    • Export Citation
  • Shigemura K, Shirakawa T, Wada Y, Kamidono S, Fujisawa M & Gotoh A 2005 Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo. Urology 66 12391244.doi:10.1016/j.urology.2005.06.076.

    • Search Google Scholar
    • Export Citation
  • Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T & Naito S 2010 Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 29 237250.doi:10.1038/onc.2009.322.

    • Search Google Scholar
    • Export Citation
  • Siu YT & Jin DY 2007 CREB – a real culprit in oncogenesis. FEBS Journal 274 32243232.doi:10.1111/j.1742-4658.2007.05884.x.

  • Skurk C, Maatz H, Kim HS, Yang J, Abid MR, Aird WC & Walsh K 2004 The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. Journal of Biological Chemistry 279 15131525.doi:10.1074/jbc.M304736200.

    • Search Google Scholar
    • Export Citation
  • Sobel RE & Sadar MD 2005 Cell lines used in prostate cancer research: a compendium of old and new lines – part 1. Journal of Urology 173 342359.doi:10.1097/01.ju.0000141580.30910.57.

    • Search Google Scholar
    • Export Citation
  • Stacey DW, Hitomi M, Kanovsky M, Gan L & Johnson EM 1999 Cell cycle arrest and morphological alterations following microinjection of NIH3T3 cells with Purα. Oncogene 18 42544261.doi:10.1038/sj.onc.1202795.

    • Search Google Scholar
    • Export Citation
  • Su-Hyeong K & Shivendra VS 2009 d,l-sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells. Molecular Cancer Therapeutics 8 19461954.doi:10.1158/1535-7163.MCT-09-0104.

    • Search Google Scholar
    • Export Citation
  • Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM & Sun H et al. 2010 Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. Journal of Clinical Investigation 120 27152730.doi:10.1172/JCI41824.

    • Search Google Scholar
    • Export Citation
  • Supakar PC, Jung MH, Song CS, Chatterjee B & Roy AK 1995 Nuclear factor κ B functions as a negative regulator for the rat androgen receptor gene and NF-κB activity increases during the age-dependent desensitization of the liver. Journal of Biological Chemistry 270 837842.doi:10.1074/jbc.270.2.837.

    • Search Google Scholar
    • Export Citation
  • Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H & Cheng L 2004 Nuclear factor-κB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clinical Cancer Research 10 55015507.doi:10.1158/1078-0432.CCR-0571-03.

    • Search Google Scholar
    • Export Citation
  • Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W & Verhoeven G 2004 Androgens, lipogenesis and prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 92 273279.doi:10.1016/j.jsbmb.2004.10.013.

    • Search Google Scholar
    • Export Citation
  • Takane KK & McPhaul MJ 1996 Functional analysis of the human androgen receptor promoter. Molecular and Cellular Endocrinology 119 8393.doi:10.1016/0303-7207(96)03800-2.

    • Search Google Scholar
    • Export Citation
  • Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW & Vogelzang NJ et al. 2003 Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. Journal of Clinical Oncology 21 26732678.doi:10.1200/JCO.2003.11.102.

    • Search Google Scholar
    • Export Citation
  • Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC & de Vere White RW 2007 GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate 67 521535.doi:10.1002/pros.20548.

    • Search Google Scholar
    • Export Citation
  • Tian B & Brasier AR 2003 Identification of a nuclear factor κ B-dependent gene network. Recent Progress in Hormone Research 58 95130.doi:10.1210/rp.58.1.95.

    • Search Google Scholar
    • Export Citation
  • Tilley WD, Marcelli M & McPhaul MJ 1990 Expression of the human androgen receptor gene utilizes a common promoter in diverse human tissues and cell lines. Journal of Biological Chemistry 265 1377613781.

    • Search Google Scholar
    • Export Citation
  • Tiniakos DG, Mitropoulos D, Kyroudi-Voulgari A, Soura K & Kittas C 2006 Expression of c-Jun oncogene in hyperplastic and carcinomatous human prostate. Urology 67 204208.doi:10.1016/j.urology.2005.07.045.

    • Search Google Scholar
    • Export Citation
  • Titus MA, Schell MJ, Lih FB, Tomer KB & Mohler JL 2005 Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research 11 46534657.doi:10.1158/1078-0432.CCR-05-0525.

    • Search Google Scholar
    • Export Citation
  • Vander Griend DJ, Antony L, Dalrymple SL, Xu Y, Christensen SB, Denmeade SR & Isaacs JT 2009 Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Molecular Cancer Therapeutics 8 13401349.doi:10.1158/1535-7163.MCT-08-1136.

    • Search Google Scholar
    • Export Citation
  • Verras M & Sun Z 2006 Roles and regulation of Wnt signaling and β-catenin in prostate cancer. Cancer Letters 237 2232.doi:10.1016/j.canlet.2005.06.004.

    • Search Google Scholar
    • Export Citation
  • Wang X, Sato R, Brown MS, Hua X & Goldstein JL 1994 SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 77 5362.doi:10.1016/0092-8674(94)90234-8.

    • Search Google Scholar
    • Export Citation
  • Wang LG, Ossowski L & Ferrari AC 2004 Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene 23 51755184.doi:10.1038/sj.onc.1207654.

    • Search Google Scholar
    • Export Citation
  • Wang LG, Liu XM & Chiao JW 2006 Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate. Carcinogenesis 27 21242132.doi:10.1093/carcin/bgl075.

    • Search Google Scholar
    • Export Citation
  • Wang LG, Johnson EM, Kinoshita Y, Babb JS, Buckley MT, Liebes LF, Melamed J, Liu XM, Kurek R & Ossowski L et al. 2008 Androgen receptor overexpression in prostate cancer linked to Purα loss from a novel repressor complex. Cancer Research 68 26782688.doi:10.1158/0008-5472.CAN-07-6017.

    • Search Google Scholar
    • Export Citation
  • Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, Sartor O, Cvitanovic L, Marshall FF, Xu Z & Chung LW 2007 cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 26 50705077.doi:10.1038/sj.onc.1210316.

    • Search Google Scholar
    • Export Citation
  • Xing N, Chen Y, Mitchell SH & Young CY 2001 Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22 409414.doi:10.1093/carcin/22.3.409.

    • Search Google Scholar
    • Export Citation
  • Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B & Sun Z 2002 Linking β-catenin to androgen-signaling pathway. Journal of Biological Chemistry 277 1133611344.doi:10.1074/jbc.M111962200.

    • Search Google Scholar
    • Export Citation
  • Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A & Weinberg RA 2004 Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117 927939.doi:10.1016/j.cell.2004.06.006.

    • Search Google Scholar
    • Export Citation
  • Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E, Chen YT, Hu YC, Wang L & Chuang KH et al. 2005 Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. Journal of Biological Chemistry 280 3355833565.doi:10.1074/jbc.M504461200.

    • Search Google Scholar
    • Export Citation
  • Yang X, Chen MW, Terry S, Vacherot F, Bemis DL, Capodice J, Kitajewski J, de la Taille A, Benson MC & Guo Y et al. 2006 Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 25 34363444.doi:10.1038/sj.onc.1209366.

    • Search Google Scholar
    • Export Citation
  • Yardy GW & Brewster SF 2005 Wnt signalling and prostate cancer. Prostate Cancer and Prostatic Diseases 8 119126.doi:10.1038/sj.pcan.4500794.

    • Search Google Scholar
    • Export Citation
  • Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C & Chang C 1998 Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. Biochemical and Biophysical Research Communications 248 361367.doi:10.1006/bbrc.1998.8974.

    • Search Google Scholar
    • Export Citation
  • Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, Goldstein JL & Brown MS 1993 SREBP-1, a basic-helix–loop–helix–leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75 187197.

    • Search Google Scholar
    • Export Citation
  • Yu X, Wang Y, Degraff DJ, Wills ML & Matusik RJ 2010 Wnt/β-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 30 18681879.doi:10.1038/onc.2010.560.

    • Search Google Scholar
    • Export Citation
  • Yuan H, Pan Y & Young CY 2004 Overexpression of c-Jun induced by quercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Letters 213 155163.doi:10.1016/j.canlet.2004.04.003.

    • Search Google Scholar
    • Export Citation
  • Yuan H, Gong A & Young CY 2005 Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 26 793801.doi:10.1093/carcin/bgi021.

    • Search Google Scholar
    • Export Citation
  • Yuan HQ, Kong F, Wang XL, Young CY, Hu XY & Lou HX 2008 Inhibitory effect of acetyl-11-keto-β-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochemical Pharmacology 75 21122121.doi:10.1016/j.bcp.2008.03.005.

    • Search Google Scholar
    • Export Citation
  • Yuen HF, Chua CW, Chan YP, Wong YC, Wang X & Chan KW 2007 Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology 50 648658.doi:10.1111/j.1365-2559.2007.02665.x.

    • Search Google Scholar
    • Export Citation
  • Zegarra-Moro OL, Schmidt LJ, Huang H & Tindall DJ 2002 Disruption of androgen function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Research 62 10081013.

    • Search Google Scholar
    • Export Citation
  • Zhang L, Charron M, Wright WW, Chatterjee B, Song CS, Roy AK & Brown TR 2004 Nuclear factor-κB activates transcription of the androgen receptor gene in Sertoli cells isolated from testes of adult rats. Endocrinology 145 781789.doi:10.1210/en.2003-0987.

    • Search Google Scholar
    • Export Citation
  • Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A & Hamburger AW 2005 The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. PNAS 102 98909895.doi:10.1073/pnas.0503829102.

    • Search Google Scholar
    • Export Citation
  • Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG & Chang C et al. 2009 NF-κB regulates androgen receptor expression and prostate cancer growth. American Journal of Pathology 175 489499.doi:10.2353/ajpath.2009.090275.

    • Search Google Scholar
    • Export Citation
  • Zhao XY, Ly LH, Peehl DM & Feldman D 1999 Induction of androgen receptor by 1α,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 140 12051212.doi:10.1210/en.140.3.1205.

    • Search Google Scholar
    • Export Citation
  • Zhao H, Whitfield ML, Xu T, Botstein D & Brooks JD 2004 Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Molecular Biology of the Cell 15 506519.doi:10.1091/mbc.E03-07-0501.

    • Search Google Scholar
    • Export Citation
  • Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P & Nikitin AY 2006 Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Research 66 78897898.doi:10.1158/0008-5472.CAN-06-0486.

    • Search Google Scholar
    • Export Citation